Related references
Note: Only part of the references are listed.Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
J. D. Jensen et al.
ANNALS OF ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
The role of Tau protein in resistance to paclitaxel
Marta Smoter et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HER2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non-small cell lung cancer
Byoung Yong Shim et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2009)
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
Satoru Tanaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer
Karen Bullock et al.
ONCOLOGIST (2008)
The CD44(+)/CD24(-) phenotype is enriched in basal-like breast tumors
Gabriella Honeth et al.
BREAST CANCER RESEARCH (2008)
Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
Pascal Seve et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2007)
Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment
K. Mimori et al.
BRITISH JOURNAL OF CANCER (2006)
Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules
Xue Zhang et al.
FASEB JOURNAL (2006)
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
T Fujita et al.
BRITISH JOURNAL OF CANCER (2006)
Microtubule associated protein (MAP)-Tau - A novel mediator of paclitaxel sensitivity in vitro and in vivo
P Wagner et al.
CELL CYCLE (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma
K Llinares et al.
MODERN PATHOLOGY (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis
C Shimizu et al.
HUMAN PATHOLOGY (2004)
Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel
M Hari et al.
CELL MOTILITY AND THE CYTOSKELETON (2003)
Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder:: A comparison with p53 nuclear accumulation
HL Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
